Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pet DNA Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pet DNA Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pet owners, breeders, and veterinarians, understanding an animal’s genetic makeup has become increasingly valuable. Mixed-breed dogs and cats may carry hidden health risks, while purebred breeding requires genetic verification to maintain breed standards and reduce inherited disorders. Pet DNA testing analyzes a pet’s DNA to reveal genetic information including breed ancestry, health status, personality traits, and potential genetic diseases. Through genetic testing, pet owners can better understand their pet’s health risks, take preventative measures, or adjust diet and lifestyle based on their pet’s genetic profile. Furthermore, some pet genetic tests can help identify a pet’s relatives, trace their family tree, or provide information on adaptability to different environments. This technology has significant application value in improving pet care and preventive medicine. For pet owners seeking personalized healthcare insights, breeders aiming to improve genetic diversity, and investors tracking the humanization of pet care, understanding this rapidly growing market’s dynamics is essential.
The global market for Pet DNA Testing was estimated to be worth USD 358 million in 2024 and is forecast to reach a readjusted size of USD 793 million by 2031, growing at a CAGR of 12.4% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5051194/pet-dna-testing
1. Product Definition and Core Service Types
Pet DNA testing analyzes a pet’s DNA (typically from a saliva swab or blood sample) to reveal genetic information including breed ancestry, health status, personality traits, and potential genetic disease risks.
Core Testing Capabilities:
Breed Identification: For mixed-breed dogs and cats (the majority of pets), DNA testing identifies the genetic signatures of various breeds present in the pet’s ancestry. Results typically include percentage breakdowns of breed contributions and comparison to reference databases of recognized breeds. “Breed reveal” has become a popular consumer engagement driver, similar to human ancestry testing.
Genetic Disease Screening: Tests screen for known genetic mutations associated with inherited diseases. For dogs, common screened conditions include progressive retinal atrophy (PRA), degenerative myelopathy (DM), multifocal retinopathy, and breed-specific conditions (e.g., von Willebrand disease in Dobermans). For cats, conditions include polycystic kidney disease (PKD), hypertrophic cardiomyopathy (HCM), and progressive retinal atrophy. Early identification allows preventive management (diet, monitoring, breeding decisions).
Physical Trait Analysis: Tests predict physical characteristics including coat color, coat pattern, coat length, eye color, body size, and other morphological traits.
Relatives and Family Tree: Some tests identify genetic relatives among other tested pets and trace lineage, valuable for breeders and owners of adopted pets.
Sample Type Segmentation:
Saliva (dominant segment, approximately 80-85% of market): Cheek swab collected by pet owner at home, mailed to laboratory. Non-invasive, painless, convenient. Preferred for direct-to-consumer testing.
Blood (10-15%): Requires veterinary collection. Higher cost but may provide more DNA quantity and enables additional clinical testing. Used primarily for breeding verification and veterinary diagnostics.
Others (5%): Including tissue samples (ear notch, umbilical cord) for specific applications.
Application Segmentation by Pet Type:
Dogs (approximately 60-65% of market value): The largest segment, driven by the popularity of mixed-breed dogs (where owners seek breed identification), purebred breeding verification, and more established genetic disease screening panels (over 250 genetic markers available for dogs vs. 40-50 for cats).
Cats (25-30%): The second-largest segment, growing faster (13-15% CAGR) as awareness of feline genetic diseases increases and databases expand.
Others (5-10%): Including horses, birds, and exotic pets.
2. Market Size Trajectory and Key Growth Drivers
The pet DNA testing market, as tracked by QYResearch, shows strong growth from USD 358 million in 2024 to USD 793 million by 2031, representing a 12.4% CAGR.
Driver 1: Humanization of Pet Care and Preventive Medicine: Pet owners increasingly treat pets as family members, willing to invest in health monitoring and personalized care. Pet medical care is the second largest segment in the pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6 billion in 2015 to £4 billion in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry increased by 12% to USD 45.3 billion in 2021. The White Paper on China’s Pet Healthy Consumption of JD shows that in 2023, 13.09 million pets entered middle age and old age, and pet aging is expected to accelerate in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry, with genetic testing playing a role in early disease detection.
Driver 2: Rising Prevalence of Purebred Pet Ownership and Breeding Verification: Responsible breeders use DNA testing to screen for inherited diseases before breeding, reducing the incidence of genetic disorders in purebred populations. Testing also verifies parentage and provides documentation for breed registration. The global purebred dog registration market (AKC, The Kennel Club, FCI) and purebred cat registration market (CFA, TICA, FIFe) each generate hundreds of thousands of annual registrations, each potentially generating testing demand.
Driver 3: Consumer Engagement and Social Sharing: “Breed reveal” results generate significant social media engagement (Instagram, TikTok, Facebook groups), similar to human ancestry testing. Pet owners share results, compare with other pets, and form online communities around test results. This viral marketing effect reduces customer acquisition costs and drives organic growth.
Driver 4: Growing Pet Medical Industry Infrastructure: According to the 2022 China Pet Medical Industry White Paper, from the perspective of market size, China’s pet medical market reached approximately RMB 67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%, indicating rapid industry expansion. Approximately 11% of pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of hospitals have increased their annual turnover year-on-year, with growth rates mainly within 5-20%. As the veterinary infrastructure expands and matures, adoption of advanced diagnostic tools including genetic testing increases.
Exclusive Observation – Direct-to-Consumer (DTC) Dominance: The pet DNA testing market is primarily DTC (70-80% online sales), similar to human ancestry testing. Marketing occurs through social media (targeted ads, influencer partnerships), search engine marketing, veterinary partnerships, and pet store presence. Repeat purchase rate is low (most pet owners test each pet once), so customer acquisition cost management is critical for profitability. Leading players including Embark Veterinary and Wisdom Panel (Mars Petcare) have invested heavily in brand building and distribution partnerships.
3. Industry Development Characteristics and Competitive Landscape
As a senior industry analyst, I observe several defining characteristics that differentiate the pet DNA testing market.
Characteristic 1 – North American Dominance with Emerging Market Growth: North America is the largest regional market, accounting for approximately 50-55% of global market share, driven by high pet ownership rates (approximately 60% of US households own a pet), high disposable income, early adoption of pet genetic testing, and strong direct-to-consumer marketing. Europe follows with approximately 25-30% share. Emerging markets such as China are experiencing significant growth (15-20% annually), driven by rising pet ownership, increasing disposable income, growing veterinary infrastructure, and increasing awareness of pet health.
Characteristic 2 – Competitive Landscape with Premium and Value Tiers: The pet DNA testing market features a two-tier competitive structure.
| Tier | Key Players | Market Characteristics |
|---|---|---|
| Premium/Comprehensive | Embark Veterinary (dog-focused), Wisdom Panel (Mars Petcare), Basepaws (Zoetis, cat-focused), Orivet | Broad disease screening (250+ markers for dogs), large reference databases, breed identification, relatives search, USD 100-200 pricing |
| Value/Specialty | DNA My Dog, EasyDNA, TellmeGen, VetGen, Royal Canin, GenSol Diagnostics, Thermo Fisher Scientific, Ancestry, Meidike Gene (China) | Basic breed identification, limited disease screening, USD 40-80 pricing, often single-species focus |
Embark Veterinary (dog-specific) and Wisdom Panel (Mars Petcare) dominate the dog DNA testing segment, together holding approximately 60-65% market share. Basepaws (acquired by Zoetis) leads the cat DNA testing segment.
Characteristic 3 – Technology and Database as Competitive Moat: Pet DNA test accuracy depends on reference database size and breed representation. Leading players have invested in building proprietary databases with hundreds of thousands of pet DNA samples across recognized breeds. Embark has the largest canine genetic database (over 500,000 dogs). Wisdom Panel has tested over 3 million pets globally. New entrants without substantial databases cannot match accuracy for rare breeds or mixed-breed pets with complex ancestry. Database accumulation creates network effects: more tests increase database size, improving accuracy for future tests.
Characteristic 4 – Dog Segment Dominance, Cat Segment Growth: Dogs represent approximately 60-65% of market value due to more established breed databases (over 350 recognized dog breeds vs. 50-70 cat breeds), more extensive disease screening panels (over 250 genetic markers for dogs vs. 40-50 for cats), higher demand for mixed-breed identification (many more mixed-breed dogs than cats), and earlier market entry. However, the cat segment is growing faster (13-15% CAGR) as awareness of feline genetic diseases increases and databases expand.
Exclusive Observation – Aging Pet Population as Growth Catalyst: The aging pet population directly benefits pet DNA testing. Older pets are more likely to develop genetic diseases, and early detection via DNA testing enables preventive management. According to the White Paper on China’s Pet Healthy Consumption of JD, 13.09 million pets entered middle age and old age in 2023, with accelerated aging expected in the next few years. As dogs enter senior years (typically 7+ years depending on breed), owners become more proactive about health screening, including genetic testing for breed-specific conditions. This demographic tailwind supports continued market growth.
4. Recent User Cases and Technical Developments (2025-2026)
**User Case – Mixed-Breed Dog Adoption: A dog owner in the United States adopted a mixed-breed rescue dog and purchased an Embark DNA test in 2025. Results revealed 40% German Shepherd, 25% Labrador Retriever, 15% Siberian Husky, 10% Boxer, and 10% Supermutt (complex ancestry). The test also identified one copy of the degenerative myelopathy (DM) mutation (carrier status, unlikely to develop disease). The owner consulted a veterinarian, who recommended annual neurological screening starting at age 7 (earlier than standard age 10). The owner shared results on social media, generating significant engagement and referral sales.
User Case – Purebred Cat Breeding Program: A TICA-registered Maine Coon breeder in Germany implemented mandatory DNA testing for all breeding cats in 2025, screening for hypertrophic cardiomyopathy (HCM), spinal muscular atrophy (SMA), and polycystic kidney disease (PKD) using Basepaws. Over 12 months, the breeder tested 30 cats, identified 4 carriers (each with one copy of the mutation for a recessive condition). Carriers were removed from breeding program or bred only with clear-tested mates. The breeder now provides DNA health certificates to kitten buyers, commanding 20-25% premium pricing over breeders not providing certification.
Exclusive Observation – Veterinary Integration and Professional Endorsement: Veterinarians have traditionally been skeptical of direct-to-consumer genetic tests, concerned about misinterpretation of results and unnecessary anxiety. However, leading test providers now offer veterinarian portals (secure access to client test results, clinical interpretation guides, continuing education modules). Wisdom Panel launched Wisdom Panel Vet in 2025, integrating with veterinary practice management software. Veterinary endorsement significantly increases test uptake among pet owners who trust their veterinarian’s recommendation. The China pet medical market (RMB 67.5 billion, 22.5% of the pet industry) represents a significant opportunity for veterinary channel growth.
5. Technical Challenges and Future Outlook (2026-2032)
Technical Challenge – Reference Database Gaps for Rare Breeds: Pet DNA test accuracy for rare or regionally concentrated breeds is limited by small sample sizes in reference databases. Owners of these breeds may receive inaccurate or uninformative results. Leading players continue database expansion through targeted sampling programs.
Technical Challenge – Clinical Validity of Genetic Markers: For some screened conditions, the genetic markers used have not been fully validated across all breeds. False positives or false negatives may occur. Transparency about marker validation status and clinical interpretation guidance is essential.
Future Technology Directions (2026-2030):
Expanded Disease Screening Panels: As veterinary genetic research advances, the number of screenable inherited diseases will expand from current 250+ for dogs to 400+ conditions, including drug sensitivities, behavioral traits, and longevity markers.
Integration with Pet Insurance and Wellness Plans: Pet insurance companies may offer premium discounts for DNA-tested pets (demonstrated lower genetic disease risk). Wellness plans may include annual DNA test updates.
Personalized Health and Nutrition Recommendations: DNA results integrated with algorithmic health recommendations: customized diet (based on metabolic markers, breed-specific nutritional needs), supplement suggestions, screening schedule, and lifestyle adjustments.
Exclusive Forecast Observation – Market Consolidation and Investment: The pet DNA testing market has attracted significant investment and acquisition interest. Basepaws was acquired by Zoetis (2022). Wisdom Panel is part of Mars Petcare (acquired 2017). Embark Veterinary has raised over USD 100 million in venture funding. Ancestry (human DNA testing leader) entered the pet DNA testing market in 2024-2025. The market research indicates continued consolidation, with larger animal health and consumer genetics companies acquiring or partnering with pet DNA testing specialists. For investors, companies with proprietary databases, veterinary integration, and distribution scale are best positioned.
6. Conclusion – Accelerating Growth in Pet Preventive Healthcare
The Pet DNA Testing market is positioned for strong growth from USD 358 million to USD 793 million at a 12.4% CAGR through 2031, driven by pet humanization, purebred breeding demand, genetic disease prevention awareness, aging pet populations, and engaging direct-to-consumer marketing. North America dominates (50%+ share), while emerging markets (China, Southeast Asia) provide accelerated growth. Dogs represent the largest segment (60-65%), with cats growing faster (13-15% CAGR). With testing costs continuing to decline and application scenarios expanding (breed verification, disease screening, personalized wellness, pet insurance integration), the market is expected to sustain double-digit growth through the forecast period. For manufacturers, key strategic priorities include reference database expansion (improving accuracy), veterinary integration (professional endorsement), cat segment expansion (faster growth), and emerging market entry (China, India). For investors, the pet DNA testing market offers attractive growth in the pet humanization megatrend, with network effects (database scale) providing competitive moats for established players.
For detailed competitive benchmarking, regional adoption analysis, sample type forecasts (saliva, blood), pet type analysis (dogs, cats, others), and 36-month rolling projections across 8 major regions, the full QYResearch report provides actionable intelligence for strategic planning and investment decision-making.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
